ストックスクリーナーアプリを入手
3.91
0.77%
0.03
前日終値:
$3.88
開ける：
$3.87
24時間の取引高:
525.35K
Relative Volume:
0.60
時価総額：
$341.88M
収益：
$32.77M
当期純損益:
$-101.98M
株価収益率:
-0.4069
EPS:
-9.6101
ネットキャッシュフロー:
$-112.43M
1週間 パフォーマンス:
-1.76%
1か月 パフォーマンス:
+1.03%
6か月 パフォーマンス:
+28.20%
1年 パフォーマンス:
-78.30%
1日の値動き範囲:
$3.77
$4.0784
1週間の範囲:
$3.525
$4.0784
52週間の値動き範囲:
$1.35
$26.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
名前
X 4 Pharmaceuticals Inc
セクター
電話
857-529-8300
住所
61 NORTH BEACON STREET, BOSTON, MA
XFOR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
3.91 | 339.25M | 32.77M | -101.98M | -112.43M | -9.6101 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-05 | 再開されました | Stifel | Buy |
| 2023-12-12 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | 再開されました | B. Riley Securities | Buy |
| 2022-12-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-12 | 開始されました | Piper Sandler | Overweight |
| 2019-12-23 | 開始されました | Oppenheimer | Outperform |
| 2019-12-18 | 開始されました | ROTH Capital | Buy |
| 2019-12-09 | アップグレード | Citigroup | Neutral → Buy |
| 2019-12-05 | 開始されました | B. Riley FBR | Buy |
| 2019-06-07 | 開始されました | Stifel | Buy |
| 2019-06-05 | 開始されました | Cowen | Outperform |
すべてを表示
X 4 Pharmaceuticals Inc (XFOR) 最新ニュース
Aug Opening: Will X4 Pharmaceuticals Inc. stock deliver long term returns2025 Technical Overview & Verified Chart Pattern Trade Signals - moha.gov.vn
Bain Capital Life Sciences Investors LLC Sells 16,351,925 Shares of X4 Pharmaceuticals, Inc. $XFOR - MarketBeat
X4 Pharmaceuticals, Inc. $XFOR Shares Sold by Acorn Capital Advisors LLC - MarketBeat
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome - Markets Financial Content
X4 PharmaSeizing Rare Opportunities, Not Acting On A Whim - RTTNews
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Does X4 Pharmaceuticals Inc (XFOR) offer a good opportunity for investors? - setenews.com
X4 Pharmaceuticals, Inc. $XFOR Shares Sold by Pale Fire Capital SE - MarketBeat
Tracking the Evolving Narrative for X4 Pharmaceuticals After Financing and Restructuring Moves - Yahoo Finance
Blood pressure drug recalled for possible cross-contamination - USA Today
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
XFOR Stock Update: Stifel Raises Target Price to $10.00 | XFOR S - GuruFocus
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness - BioSpace
Stronger 2025 Outlook And Fragile X Trial Start Might Change The Case For Investing In Mirum (MIRM) - Yahoo Finance
How X4 Pharmaceuticals Inc. stock reacts to oil prices2025 Technical Overview & Stepwise Swing Trade Plans - Newser
Is X4 Pharmaceuticals Inc. (48Q0) stock a safe buy pre earningsFed Meeting & Intraday High Probability Alerts - Newser
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Take off with X4 Pharmaceuticals Inc (XFOR): Get ready for trading - Setenews
Why pension funds invest in X4 Pharmaceuticals Inc. (48Q0) stockWeekly Earnings Recap & Weekly Breakout Opportunity Watchlist - Newser
Is X4 Pharmaceuticals Inc. stock positioned for long term growthJuly 2025 Gainers & Comprehensive Market Scan Reports - Newser
Will X4 Pharmaceuticals Inc. (48Q0) stock profit from AI boomTrade Ideas & Fast Exit and Entry Strategy Plans - Newser
An analyst sees good growth prospects for Nano X Imaging Ltd (NNOX) - Setenews
X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia (NASDAQ:XFOR) - Seeking Alpha
Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome - Yahoo Finance
X4 Pharmaceuticals (NASDAQ:XFOR) Stock Rating Lowered by Wall Street Zen - Defense World
Layoff Tracker: Adare Shuts Down Philadelphia Plant, Leaving 137 Jobless - BioSpace
SKYRIZI® Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance - Investing News Network
Will X4 Pharmaceuticals Inc. stock deliver long term returns2025 Momentum Check & Free High Accuracy Swing Entry Alerts - moha.gov.vn
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness - Morningstar
Can X4 Pharmaceuticals Inc. stock deliver sustainable ROE2025 Macro Impact & Low Volatility Stock Recommendations - moha.gov.vn
Earnings Report: Can X4 Pharmaceuticals Inc. stock sustain institutional interestTrade Risk Summary & AI Powered Buy and Sell Recommendations - moha.gov.vn
Investors Don't See Light At End Of Universe Pharmaceuticals INC's (NASDAQ:UPC) Tunnel And Push Stock Down 31% - simplywall.st
Looking at the Narrative for X4 Pharmaceuticals After Leadership Changes and New Financing - Yahoo Finance
Head-To-Head Contrast: Werewolf Therapeutics (NASDAQ:HOWL) versus X4 Pharmaceuticals (NASDAQ:XFOR) - Defense World
X4 Pharmaceuticals (NASDAQ:XFOR) Upgraded to Hold at Wall Street Zen - Defense World
Is X4 Pharmaceuticals Inc. stock positioned for digital transformation2025 Price Action Summary & Comprehensive Market Scan Insights - newser.com
Why X4 Pharmaceuticals Inc. (48Q0) stock remains top ratedWeekly Trend Report & AI Enhanced Trading Alerts - newser.com
Will X4 Pharmaceuticals Inc. stock remain a Wall Street favorite2025 Short Interest & Growth Oriented Trading Recommendations - newser.com
X4 Pharmaceuticals Inc (XFOR) Performance and Fundamentals Dashboard tells a completely different story - Setenews
How to build a dashboard for X4 Pharmaceuticals Inc. stockWeekly Trade Analysis & Growth Oriented Trading Recommendations - newser.com
X 4 Pharmaceuticals Inc (XFOR) 財務データ
収益
当期純利益
現金流量
EPS
X 4 Pharmaceuticals Inc (XFOR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Baldry Mark | Chief Commercial Officer |
May 16 '25 |
Buy |
2.48 |
1,032 |
2,561 |
25,337 |
| Ragan Paula | President and CEO |
Jan 24 '25 |
Sale |
0.45 |
76,473 |
34,719 |
1,087,386 |
| Mostafa Adam S. | Chief Financial Officer |
Jan 24 '25 |
Sale |
0.45 |
74,773 |
33,947 |
0 |
| Baldry Mark | Chief Commercial Officer |
Jan 24 '25 |
Sale |
0.45 |
29,159 |
13,241 |
94,123 |
| DiBiase Mary | Chief Operating Officer |
Jan 24 '25 |
Sale |
0.45 |
22,258 |
10,094 |
490,980 |
| Arbet-Engels Christophe | Chief Medical Officer |
Jan 24 '25 |
Sale |
0.45 |
11,624 |
5,284 |
14,207 |
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):